Optimistic Buy Rating for Achieve Life Sciences Driven by Cytisinicline’s Regulatory Progress and Strategic Focus on Smoking and Vaping Cessation

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Achieve Life Sciences (ACHV – Research Report). The associated price target remains the same with $10.00.

Jason McCarthy’s rating is based on Achieve Life Sciences’ progress in advancing its lead product, cytisinicline, towards regulatory approval. The company has successfully gathered long-term safety data, a critical requirement for the New Drug Application (NDA) submission for cytisinicline in smoking cessation, which is on track for June 2025. The Data Safety Monitoring Committee has conducted multiple safety reviews with no concerns, reinforcing the drug’s safety profile.
Additionally, Achieve Life Sciences is planning a Phase 3 study for vaping cessation, which has received positive feedback from the FDA, indicating a clear path forward for further clinical development. The company’s strategic focus on both smoking and vaping cessation, coupled with a robust clinical trial design, positions it well for future growth. These factors contribute to McCarthy’s optimistic outlook and Buy rating for the stock.

In another report released today, Raymond James also maintained a Buy rating on the stock with a $20.00 price target.

ACHV’s price has also changed dramatically for the past six months – from $4.530 to $2.650, which is a -41.50% drop .